Patents Assigned to Università Cattolica del Sacro Cuore
-
Publication number: 20240350556Abstract: The present invention provides to compositions comprising cord blood platelet-rich plasma (CB-PRP) for the treatment of ocular diseases as well as methods of treatments of ocular diseases in which therapeutic effective amounts of blood platelet-rich plasma (CB-PRP) are administered to a subject in need thereof.Type: ApplicationFiled: July 2, 2024Publication date: October 24, 2024Applicants: Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCSInventors: Stanislao RIZZO, Maria Cristina SAVASTANO, Alfonso SAVASTANO, Luciana TEOFILI, Maria BIANCHI, Marcello PANI
-
Publication number: 20230287061Abstract: The present invention relates to new antimicrobial peptides of plant origin, with bacteriostatic and/or bactericidal effect against Gram positive and Gram negative bacteria, compositions including them and use thereof.Type: ApplicationFiled: August 9, 2021Publication date: September 14, 2023Applicant: Università Cattolica del Sacro CuoreInventors: Daniela BASSI, Pier Sandro COCCONCELLI, Francesca DILDA, Francesca BUGLI, Luigi ORRU', Antonella LAMONTANARA
-
Publication number: 20230285520Abstract: The present invention relates to a protein having proteolytic activity inducible and activable by the experimenter in the cytosol or in the secretory pathway, and uses thereof for controlling the maturation in a vital cell of a protein subject to proteolytic cleavage, and in a purification process of recombinant proteins.Type: ApplicationFiled: July 27, 2021Publication date: September 14, 2023Applicants: Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCSInventors: Claudio GRASSI, Cristian RIPOLI, Pietro RENNA
-
Publication number: 20230240788Abstract: A device for processing a video stream related to a specific operative procedure. The device includes: a video stream reception interface, a processor, and a memory storing instructions, such that when the instructions are executed by the processor, they configure the device for: receiving, via the video stream reception interface, the video stream having a sequence of images including an image to be processed which represents at least a portion of an anatomical element, the image to be processed being formed by processing elements; determining, by a processing function, whether or not a criterion is satisfied in the image to be processed; determining a state of progress associated with the image to be processed based on whether or not the criterion is satisfied, the state of progress being representative of a state of progress of an operative step of the specific operative procedure.Type: ApplicationFiled: June 11, 2021Publication date: August 3, 2023Applicants: FONDATION DE COOPERATION SCIENTIFIQUE, Université de Strasbourg, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, UNIVERSITÀ CATTOLICA DEL SACRO CUORE, INSTITUT DE RECHERCHE CONTRE LES CANCERS DE L'APPAREIL DIGESTIFInventors: Nicolas PADOY, Pietro MASCAGNI, Bernard DALLEMAGNE
-
Publication number: 20230149473Abstract: The present invention provides to compositions comprising cord blood platelet-rich plasma (CB-PRP) for the treatment of ocular diseases as well as methods of treatments of ocular diseases in which therapeutic effective amounts of blood platelet-rich plasma (CB-PRP) are administered to a subject in need thereof.Type: ApplicationFiled: November 17, 2022Publication date: May 18, 2023Applicants: Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCSInventors: Alfonso SAVASTANO, Nicoletta ORLANDO, Caterina Giovanna VALENTINI, Tomaso CAPOROSSI, Stanislao RIZZO
-
Patent number: 10941399Abstract: The present invention relates to chimeric RNA oligonucleotides that are single-stranded oligonucleotides. These compounds are capable of targeting particular genes and reducing DNA methyltransferase activity. Accordingly, these compounds are particularly useful in the treatment of disease associated with aberrant DNA methyltransferase activity, such as cancer or a genetic disorder.Type: GrantFiled: April 13, 2012Date of Patent: March 9, 2021Assignees: Beth Israel Deaconess Medical Center, Inc., Università Cattolica del Sacro CuoreInventors: Annalisa Di Ruscio, Alexander K. Ebralidze, Daniel G. Tenen, Giuseppe Leone
-
Patent number: 9994524Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen II-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.Type: GrantFiled: March 24, 2017Date of Patent: June 12, 2018Assignees: CONSIGLIO NAZIONALE DELLE RICERCHE, UNIVERSITÀ CATTOLICA DEL SACRO CUOREInventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo′
-
Patent number: 9630954Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen ll-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.Type: GrantFiled: April 2, 2013Date of Patent: April 25, 2017Assignees: Consiglio Nazionale delle Ricerche, Università Cattolica del Sacro CuoreInventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo′
-
Publication number: 20140171492Abstract: The present invention relates to chimeric RNA oligonucleotides that are single-stranded oligonucleotides. These compounds are capable of targeting particular genes and reducing DNA methyltransferase activity. Accordingly, these compounds are particularly useful in the treatment of disease associated with aberrant DNA methyltransferase activity, such as cancer or a genetic disorder.Type: ApplicationFiled: April 13, 2012Publication date: June 19, 2014Applicants: Universita Cattolica del Sacro Cuore, Beth Israel Deaconess Medical Center, Inc.Inventors: Annalisa Di Ruscio, Alexander K. Ebralidze, Daniel G. Tenen, Giuseppe Leone
-
Publication number: 20120094306Abstract: The present invention relates to methods and kits for a predictive evaluation of the effectiveness of a taxane-including treatment of a tumour or of cancer cells.Type: ApplicationFiled: June 16, 2009Publication date: April 19, 2012Applicant: UNIVERSITA CATTOLICA DEL SACRO CUOREInventors: Giovanni Scambia, Maria Gabriella Ferrandina, Cristiano Ferlini
-
Patent number: 5176911Abstract: Topical pharmaceutical compositions, suited for the use in gynecology and urology, comprise as active principles selected Lactobacillus strains isolated from vaginal or urologic habitat of asymptomatic patients.Type: GrantFiled: August 2, 1989Date of Patent: January 5, 1993Assignees: Universita Cattolica del Sacro Cuore, Dr. A. Tosi Farmaceutici S.r.l.Inventors: Silvana Tosi, Giancarla Dondi, Vittorio Bottazzi, Franco Dellaglio, Lorenzo Morelli